Medtronic’s In.Pact Admiral 200- and 250-mm DCBs Approved in Europe

September 7, 2021—Medtronic announced CE Mark approval and the European launch of the 200- and 250-mm In.Pact Admiral drug-coated balloons (DCBs).

According to the company, the newly approved sizes of the In.Pact Admiral DCB are intended to treat long complex femoropopliteal lesions efficiently in patients with peripheral artery disease (PAD). The lengths enable physicians to treat longer lesions using a single DCB instead of multiple DCBs.

Professor Thomas Zeller, MD, who is director of the Department of Angiology at Universitaets-Herzzentrum in Freiburg-Bad Krozingen, Germany, performed the first case using the new sizes of the In.Pact Admiral DCB in Europe.

“Patients with superficial femoral artery disease often present with longer and more complex lesions as time goes on, which makes it challenging to effectively treat the entire segment,” commented Prof. Zeller in Medtronic’s announcement. “We know the In.Pact Admiral DCB is effective in providing durable results, and now with the longer sizes, it is a more efficient treatment option for these difficult to treat lesions. Using the new sizes of the In.Pact Admiral DCB could potentially lead to saving both time and money by using one balloon instead of multiple balloons.”

The 200- and 250-mm In.Pact Admiral DCB lengths received FDA approval in May 2018, including for the treatment of in-stent restenosis and lesions up to 360 mm in length, noted Medtronic.